Financials in USD. Standardized financial statements.
A compact view of how HLS Therapeutics Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $56.47M | $56.62M | $63.07M | $61.47M | $60.01M | $56.11M | $54.16M | $61.41M | $75.08M | $53.38M |
| Revenue Growth? | -0.3% | -10.2% | +2.6% | +2.4% | +7.0% | +3.6% | -11.8% | -18.2% | +40.7% | 0.0% |
| Cost of Revenue? | $32.46M | $9.00M | $7.62M | $4.98M | $3.97M | $3.63M | $1.93M | $2.60M | $4.14M | -$104,158.917 |
| Gross Profit? | $24.01M | $47.62M | $55.45M | $56.49M | $56.04M | $52.48M | $52.23M | $58.82M | $70.95M | $53.49M |
| Gross Margin? | +42.5% | +84.1% | +87.9% | +91.9% | +93.4% | +93.5% | +96.4% | +95.8% | +94.5% | +100.2% |
| Operating Expenses? | $28.19M | $55.31M | $55.45M | $69.98M | $62.32M | $64.57M | $56.86M | $51.18M | $47.66M | $1.36M |
| Operating Income? | -$4.18M | -$7.69M | -$10.35M | -$13.44M | -$6.28M | -$12.09M | -$4.63M | $7.64M | $23.29M | -$1.26M |
| EBITDA? | $18.02M | $17.22M | $12.88M | $17.28M | $25.19M | $24.42M | $20.50M | $37.63M | $56.40M | $33.29M |
| Income Before Tax | -$13.10M | -$15.58M | -$27.80M | -$23.72M | -$11.81M | -$16.30M | -$20.46M | -$28.80M | -$1.15M | -$1.04M |
| Income Tax Expense | -$452,789 | $4.07M | -$272,000 | -$124,000 | $1.31M | -$968,000 | -$911,000 | -$4.00M | $4.95M | -$164,422.29 |
| Net Income? | -$12.65M | -$19.66M | -$27.53M | -$23.60M | -$13.12M | -$15.33M | -$19.55M | -$24.81M | -$6.10M | -$874,934.901 |
| EPS? | $-0.40 | $-0.62 | $-0.85 | $-0.73 | $-0.41 | $-0.48 | $-0.67 | $-0.92 | $-0.24 | $-0.04 |
| Diluted EPS? | $-0.40 | $-0.62 | $-0.85 | $-0.73 | $-0.41 | $-0.48 | $-0.67 | $-0.92 | $-0.24 | $-0.04 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality